<Page>
----------------------------
OMB APPROVAL
----------------------------
OMB Number: 3235-0060
Expires: May 31, 2000
Estimated average burden
hours per response.....5.00
----------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 30, 2001
------------------------------
TRIANGLE PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 000-21589 56-1930728
- ----------------------------- --------------------------- ----------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
4 University Place, 4611 University Drive, Durham, North Carolina 27707
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 493-5980
-----------------------------
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<Page>
Item 5. Other Events.
On November 30, 2001, Triangle Pharmaceuticals entered into a Master
Loan and Security Agreement with Wells Fargo Equipment Finance, Inc., a copy of
which is attached hereto as Exhibit 10.1. and is incorporated herein by
reference
Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits.
(c) Exhibits. The following documents are filed as exhibits to this
Report:
10.1 Master Loan and Security Agreement dated November 30, 2001
between Triangle Pharmaceuticals, Inc. and Wells Fargo
Equipment Finance, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Triangle Pharmaceuticals, Inc.
---------------------------------------------
(Registrant)
December 7, 2001 /s/ Robert F. Amundsen, Jr.
- ------------------------------- ---------------------------------------------
Date (Signature)
Name: Robert F. Amundsen, Jr.
Title: Executive Vice President & Chief
Financial Officer